BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CTMSS - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CTMSS
X-ORIGINAL-URL:https://clinicaltmssociety.org
X-WR-CALDESC:Events for CTMSS
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20220101T000000
END:STANDARD
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20240310T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20241103T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250204T080000
DTEND;TZID=America/New_York:20250204T200000
DTSTAMP:20260405T182537
CREATED:20250113T160420Z
LAST-MODIFIED:20250312T142724Z
UID:1933-1738656000-1738699200@clinicaltmssociety.org
SUMMARY:Grand Rounds Webinar: Recent Advances in Neurotherapeutics for Child and Adolescent Mood Disorders
DESCRIPTION:> >Register Now <<\nJoin the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: "Recent Advances in Neurotherapeutics for Child and Adolescent\nMood Disorders" \nSpeaker: Paul E. Croarkin\, DO\, MS\nJoin Dr. Croarkin for an update on the clinical implementation and research of transcranial magnetic stimulation for adolescents with depression. Dr. Croarkin will also review recent\, ongoing\, and planned research focused on neurotherapeutics. \nAt the end of the presentation\, attendees will:\n\nDemonstrate a working knowledge of noninvasive brain stimulation modalities such as transcranial electrical stimulation\, transcranial magnetic stimulation\, and electroconvulsive therapy.\nDemonstrate the ability to discuss recent studies adapting transcranial magnetic stimulation for adolescents with major depressive disorder.\nDemonstrate the ability to discuss recent research with ketamine in adolescents and to discuss potential future studies and related challenges with psychedelic therapeutic.\n\nTake advantage of our live Q&A session at the conclusion of the webinar. \n*Registered attendees will receive access to the on-demand video recording by Friday\, Friday\, February 7\, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nOne hour CME credit is available - Click here for CE Language \nWhen:\nUSA - February 4\, 2025 at 8:00pm EST | 5:00pm PST \nUK- February 5\, 2025 at 1:00am\nGMT \nAustralia- February 5\, 2025 at\n12:00pm AEDT \nCost:\nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \nAll Grand Rounds are recorded and available On-Demand. Recordings are available by the Friday after the live event. \n> >Register Now <<\nAbout the Speaker: Paul Croarkin\, DO\, MS\n \nDr. Croarkin is the Ervin A. and Margaret C. Mueller Director of the Children’s Research Center at Mayo Clinic and the Chair for Pediatric\nResearch in the Department of Pediatrics and Adolescent Medicine. He is a professor of Psychiatry\, Pediatrics\, and Pharmacology in the Mayo Clinic College of Medicine and Science. He serves as the Editor-in-Chief for the Journal of Child and Adolescent Psychopharmacloogy. \nDr. Croarkin completed medical school at the University of North Texas Health Science Center. He then completed residency training in psychiatry at Naval Medical Center San Diego\, where he served as chief resident. Following this\, Dr. Croarkin served as a US Navy psychiatrist in an academic role at Walter Reed Army Medical Center and in an operational setting as a psychiatrist embedded with the 24th Marine Expeditionary Unit in North Babil during Operation Iraqi Freedom. He returned for clinical and research training in child\nand adolescent psychiatry at UT Southwestern Medical Center in Dallas\, again serving as chief resident. He earned a Master of Science degree with distinction in clinical science from the Graduate School of Biomedical Sciences at UT Southwestern Medical Center. Thereafter\, he joined the Mayo Clinic Department of Psychiatry and Psychology. \nAn expert in child\, adolescent\, and adult mood disorders\, neurotherapeutics\, and psychopharmacology\, Dr. Croarkin conducts research to develop innovative diagnostic and treatment approaches for children and adolescents. His research has been funded by the National Alliance for Research on Schizophrenia and Depression\, the National Institutes of Health\, and industry partnerships. His team focuses on adapting and innovating neurotherapeutics for youth with psychiatric disorders while studying GABAergic and glutamatergic\nneurotransmission. These efforts have informed and supported the clinical implementation of transcranial magnetic stimulation interventions for adolescents with depression. His findings have been published in numerous peer-reviewed journals\, including The Journal of the American Academy Child and Adolescent Psychiatry\, JAMA Psychiatry\, and Neuropsychopharmacology. \n> >Register Now <<
URL:https://clinicaltmssociety.org/event/advances-in-neurotherapeutics-for-children/
LOCATION:Zoom
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2025/01/Grand-Rounds-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20250107T200000
DTEND;TZID=America/Los_Angeles:20250107T210000
DTSTAMP:20260405T182537
CREATED:20241210T144604Z
LAST-MODIFIED:20250312T142843Z
UID:1703-1736280000-1736283600@clinicaltmssociety.org
SUMMARY:Grand Rounds Webinar: "Oops\, I did it again": TMS as a Tool to Promote Sobriety and Decrease Drug and Alcohol Relapse
DESCRIPTION:> >Register Now <<\nJoin the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: "Oops\, I did it again": TMS as a Tool to Promote Sobriety and Decrease Drug and Alcohol Relapse. \nSpeaker: Colleen A. Hanlon\, PhD\nJoin us for an insightful session on Transcranial Magnetic Stimulation (TMS) as an innovative treatment for addiction. This session will explore the FDA approved use of TMS for smoking cessation\, European clearance for stimulant use disorder\, and emerging evidence supporting its application in alcohol use disorders. Learn about the mechanisms of action\, current clinical research\, and practical strategies for integrating TMS into your addiction treatment protocols. Designed for physicians and mental health providers\, this session will provide valuable insights into how TMS can enhance patient outcomes and expand treatment options for substance use disorders. \nAt the end of the presentation\, attendees will:\n- Identify the current FDA indication for TMS in smoking cessation and discuss the emerging evidence supporting its use in stimulant and alcohol use disorders.\n- Describe the mechanisms of action of TMS in the treatment of addiction and how it modulates brain activity to reduce substance use.\n- Evaluate the mechanisms of action of TMS in the treatment of addiction and how it modulates brain activity to reduce substance use. \nTake advantage of our live Q&A session at the conclusion of the webinar. \n*Registered attendees will receive access to the on-demand video recording by Friday\, January 10\, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nOne hour CME credit is available - Click here for CE Language \nWhen:\nUSA - January 7\, 2025 at 8:00pm EST | 5:00pm PST\nUK- January 8\, 2025 at 1:00am GMT\nAustralia- January 8\, 2025 at 12:00pm AEDT \nCost:\nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \nAll Grand Rounds are recorded and available On-Demand. Recordings are available by the Friday after the live event. \n> >Register Now <<\nAbout the Speaker: Colleen A. Hanlon\, PhD\n \nVice President\, Medical Affairs\, BrainsWay\nProfessor (adjunct)\, Wake Forest University School of Medicine \nDr. Hanlon is an internationally recognized thought-leader in the development and expansion of non-invasive neuromodulation therapeutics for new populations. \nShe is currently serving as the Vice President of Medical Affairs for BrainsWay and Director of their Innovation Team. Before coming to BrainsWay she was a tenured professor at the Wake Forest School of Medicine. There she ran a multidisciplinary research program devoted to developing brain-circuit based interventions for individuals struggling with drug and alcohol use disorders. She has nearly 20 years of clinical research experience in transcranial magnetic stimulation (TMS) and brain imaging. Recognized as a pioneer int TMS for addiction\, Dr. Hanlon received over $12 million in National Institute of Health funding\, led over 15 clinical studies of TMS\, published over 100 peer-reviewed publications\, and mentored over 75 trainees in brain imaging and TMS. \nShe received her undergraduate degree from the University of Florida\, a Ph.D. in neurobiology from Duke University wherein she focused on motor recovery after stroke and in Parkinsons Disease using functional MRI. She did a postdoctoral fellowship at Wake Forest University wherein she first became interested in neuromodulation. \nIn 2023\, she was given the prestigious International Brain Stimulation Early Career Investigator award and she is the senior author on the first “Consensus Paper” published by a group of over 70 scientists from over 10 countries outlining the path forward for Non-Invasive Therapeutic Development for Addiction. \nIn addition to advancing the science and evidence for TMS for various indications\, she also participates in the research training and education community at local\, national\, and international levels. She has directed the Advanced TMS Training Course sponsored by the National Center for Neuromodulation for Rehabilitation and has served on the grassroots Advocacy committee and Public Policy committees of several scientific organizations devoted to expanding access to care for individuals with drug and alcohol use disorders. \n  \n> >Register Now <<
URL:https://clinicaltmssociety.org/event/tms-to-promote-sobriety/
LOCATION:Zoom
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/12/Grand-Rounds-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241112T120000
DTEND;TZID=America/New_York:20241112T130000
DTSTAMP:20260405T182537
CREATED:20241017T005549Z
LAST-MODIFIED:20241113T145135Z
UID:1172-1731412800-1731416400@clinicaltmssociety.org
SUMMARY:Non-Invasive Brain Stimulation to Treat Chronic Pain Targets\, Mechanisms and Clinical Outcomes
DESCRIPTION:> >Watch Now <<\nYou are invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series\, Non-Invasive Brain Stimulation to Treat Chronic Pain Targets\, Mechanisms and Clinical Outcomes\, presented by Daniel Ciampi de Andrade\, MD\, PhD. \nDr. Daniel Ciampi de Andrade is a clinical neurologist currently focused on teaching and doing research on chronic pain. He has a strong interest on the use of rTMS for the management of neurological diseases\, chronic pain in particular. As rTMS enter guidelines for the managements of chronic pain\, Dr. Daniel Ciampi de Andrade will provide an update on the mechanisms of action of rTMS for pain management\, and how it can be used to aid people with chronic pain in their quest for adequate pain relief.\nAt the end of this presentation\, attendees will: \n\nHave a clear understanding on how chronic pain syndromes are classified.\nHave a general knowledge of the treatment options for the most common pain syndromes.\nUnderstand how neuromodulation\, in particular rTMS\, can be added to the treatment plan as backed up by evidence.\n\nTake advantage of our live Q&A session at the conclusion of the webinar. \nOne hour CME credit is available - Click here for CE Language \nDate/Time: \nUSA - November 12\, 2024 at 12:00pm EST | 9:00am PST\nUK- November 12\, 2024 at 5:00pm GMT\nAustralia- November 13\, 2024 at 4:00am AEDT \nFormat: Live Webinar \nCost: Members: $25 | Non-members $50 | Trainee Members FREE \nCan't make this time and date? All Grand Rounds are recorded and available On-Demand to all registered attendees. Recordings are available Friday after the live event. \n\nSpeaker: Daniel Ciampi de Andrade\, MD\, PhD \n \nDr. Daniel Ciampi de Andrade is an associate professor and researcher at the Center of Neuroplasticity and Pain\, Department of Health Science and technology and Faculty of Medicine\, Aalborg University\, Denmark. \nDr. Daniel Ciampi de Andrade trained as a clinical neurologist at the University of Sao Paulo\, Brazil\, and in France (Université Paris-Saclay /Université Paris XII). He trained with Didier Bouhassira\, Nadine Attal and Jean-Pascal Lefaucheur during his stay in Paris\, France\, coming back to Sao Paulo\, Brazil in 2009. He then was appointed coordinator of the Multidisciplinary Pain Center of the Neurology Department\, at the University of Sao Paulo. This center was founded by his mentor\, Professor Manoel Jacobsen Teixeira\, in 1974 and is one of the largest pain centers in Latin America. Dr. Daniel Ciampi de Andrade co-founded and was vice chair of the Medical Research Laboratory of “invasive neuroscience” from 2019 to 2021. \nIn 2021 he moved to Aalborg and joined CNAP. His research has been focused on pain in neurological diseases and neuromodulation for pain relief. In particular\, he has performed research on how pain can influence cortical connectivity and how this information can be used to inform personalized treatment approaches. \nDr. Daniel Ciampi de Andrade has been serving as Vice-Chair of EFIC´s Research Committee since 2024\, section editor of the European Journal of Pain since 2016\, and advisory Board of Pain Reports since 2018. He as published more than 180 peer-reviewed studies\, along with pain book editing and several international book chapters. He received a European Research Council grant that will allow him to continue research\, paired with an amazing team of colleagues at CNAP\, to further explore the effects of pain in the human brain. \n> >Watch Now <<\n\n  \n\n\n\nWhen\nNovember 12th\, 2024 from  9:00 AM to 10:00 AM\n\n\n\nLocation\n\nUnited States\n\n\n\n\nContact\n\nPhone: info@clinicaltmssociety.org\nEmail: info@clinicaltmssociety.org\n\n\n\n\nEvent Fee(s)\n\n\n\n\nFee Level\n\n\n\nWebinar Registration | Member\n$25.00\n\n\nWebinar Registration | Non-Member\n$50.00\n\n\nWebinar Registration | Student\n$0.00\n\n\nWebinar Registration | Associate Member\n$25.00\n\n\nSpeaker Price\n-$50.00
URL:https://clinicaltmssociety.org/event/non-invasive-brain-stimulation-to-treat-chronic-pain-targets-mechanisms-and-clinical-outcomes/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/November_intro_slide.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20241107T080000
DTEND;TZID=UTC:20241107T170000
DTSTAMP:20260405T182537
CREATED:20241107T205252Z
LAST-MODIFIED:20250508T191440Z
UID:1539-1730966400-1730998800@clinicaltmssociety.org
SUMMARY:CTMSS On-Demand Webinar: An Introduction to TMS
DESCRIPTION:>>WATCH NOW<<\n*NEWLY UPDATED* CTMSS On-Demand Webinar: An Introduction to TMS\nRelease Date: January 1\, 2023 \nExpiration Date: December 31\, 2024 \nThe Clinical TMS Society is offering a 4 part on-demand webinar focused on the introduction to TMS. \nCTMSS On-Demand Webinar: An Introduction to TMS is geared primarily for new clinicians and TMS operators/technicians. In addition\, experienced clinicians and technicians who seek a stronger knowledge base would also benefit from the review and updates. \nParticipants will learn: \n\nthe history of rTMS\, including a knowledge of indications\, clinical efficacy\, review of data;\na review of the significant scientific literature giving rise to the technology's adoption;\nan understanding of practical office implementation;\na review of the evidence for conditions other than depression\n\nFormat: On-Demand Webinar \nCost: \n\nCTMSS Members | $150 USD\nNon-members | $300 USD\n\nYou will receive immediate access to the video. \n\n\n\nPresenters: \n\nDebra Stultz\, MD\, FCTMSS \nDr. Debra J. Stultz is the Director and Owner of Stultz Sleep and Behavioral Health in Barboursville\, West Virginia. Dr. Stultz earned her medical degree from Marshall University School of Medicine in Huntington\, West Virginia. She completed a residency in psychiatry and a fellowship in child/adolescent psychiatry through West Virginia University at their Charleston Division through Charleston Area Medical Center in Charleston\, West Virginia. She is board certified in psychiatry\, sleep medicine\, and behavioral sleep medicine.  With a special interest in Narcolepsy\, she treats a variety of sleep disorders and psychiatric issues.  Her specialty in psychiatry is treatment-resistant depression. She is also the editor for the Clinical TMS Society Newsletter\, on their Board of Directors\, Co-Chair of the Education Committee\, and the chairman of the TMS and Sleep Disorders Affinity Group. \n\nJonathan Becker\, DO \nDr. Becker completed his undergraduate and Masters degrees in Developmental Psychology at Tulane University in New Orleans before attending Des Moines University for medical school. He completed his psychiatry residency program at Vanderbilt University and served as a faculty member there for 7 years. While at Vanderbilt\, Dr. Becker served as the medical director of the neuromodulation service from 2017 – 2022. He joined the Neuroscience and TMS Treatment Center in Brentwood\, TN in January 2021. He is an active member of the Clinical TMS Society and a member of the Education Committee. \n\nNicholas Mischel\, MD\, PhD\nDr. Mischel is an Assistant Professor and Director of Interventional Psychiatry and Neuromodulation Research at Wayne University School of Medicine\, in their Department of Psychiatry and Behavioral Neurosciences. He completed his psychiatry residency at Duke University Medical Center\, focusing on brain stimulation clinical/translational research. He now focuses on medication-resistant mood disorders using rTMS and rapid-acting antidepressant medication infusions. He is a member of the Clinical TMS society and is on the Outreach and Education Committees. \nSandeep Vaishnavi\, MD\, PhD \nDr. Vaishnavi received his medical degree from the University of Alabama at Birmingham and completed his residency at Duke University. He completed a visiting fellowship in Transcranial Magnetic Stimulation at Duke University. He is an Adjunct Associate with the Department of Medicine-Pulmonary at Duke University\, is a faculty member with the Duke Visiting Fellowship program in Transcranial Magnetic Stimulation\, is a member of the faculty network for the Duke Institute for Brain Sciences\, is Director of Mindpath Care Centers Clinical Trails Institute\, and a member of the Corporate Governance Board for MindPath Care Centers. He is a member of Clinical TMS Society and is on the Education Committee. \n 
URL:https://clinicaltmssociety.org/event/ctmss-on-demand-webinar-an-introduction-to-tms-2/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/11/PULSES-On-Demand-Thumbnail_V2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241107
DTEND;VALUE=DATE:20241108
DTSTAMP:20260405T182537
CREATED:20241107T205012Z
LAST-MODIFIED:20260130T154309Z
UID:1528-1730937600-1731023999@clinicaltmssociety.org
SUMMARY:Residents\, Trainee Doctors\, & Medical Students | CTMSS Education Slide Deck: Transcranial Magnetic Stimulation (TMS) - An Introduction
DESCRIPTION:>>WATCH NOW<<\nLearning objectives: \nPart 1: TMS in Depression \n\nUnderstand the evidence for transcranial magnetic stimulation (TMS) as a treatment for depression\nDescribe where TMS falls in a major depressive disorder (MDD) treatment algorithm\nKnow the history of TMS\nUnderstand potential mechanisms of actions of TMS\nKnow the efficacy rate of TMS for MDD from scientific literature\n\nPart 2: Beyond Depression \n\nKnow FDA cleared psychiatric indications for TMS\nUnderstand the basic neurobiology of OCD and addictions as related to the potential mechanism of TMS\nReview the data supporting the use of TMS for OCD and smoking cessation\nIdentify the potential risks of TMS\nUnderstand patient appropriateness for TMS based on demographics\, diagnosis\, and treatment history\n\nCost: Free\nPlease register to view the presentation. On-demand video will populate at the bottom of this page once registered.  To access the powerpoint presentation slide deck\, you must also complete the Education Slide Deck Member User Agreement. At the bottom of this recording you will be prompted to complete a brief survey.  \n\nSpeakers: Kristin Raj\, MD & Suzanne Kerns\, MD \nDr. Raj specializes in the treatment of mood disorders with expertise in neuromodulation and in the psychopharmacological management of the bipolar disorder. She is Chief of Interventional Psychiatry and Chief of the Bipolar Clinic at Stanford University. She is the director of education for interventional psychiatry where she manages resident and fellow education in brain stimulation and the development of didactics. She is also director of the neuroscience curriculum for the psychiatry residency where she has worked to create and assess a new series of interactive lectures. She trained in biomedical engineering in undergraduate at Case Western Reserve University and completed her medical degree and psychiatry residency at Stanford University. She currently serves on the Board of Directors and the Education Committee of the Clinical TMS Society. \nDr. Kerns completed her undergraduate studies at the University of North Carolina in Chapel Hill. She attended medical school at the University of Sydney in Australia\, followed by a psychiatry residency at Duke University Medical Center. Dr. Kerns subsequently completed a year-long Fellowship in Brain Stimulation at the Medical University of South Carolina (MUSC) under the guidance of Dr. Mark George\, a founding father of TMS. After several years of private practice at Seattle Neuropsychiatric Treatment Center with a faculty appointment at the University of Washington\, she returned to MUSC\, where she is now an Assistant Professor of Psychiatry on the Brain Stimulation Service.  Dr. Kerns is a past member of the Board of Directors of the Clinical TMS Society\, past Member-at-Large on the CTMSS Executive Committee\, past Co-Chair of the CTMSS Education Committee\, and she continues to proudly serve as a member of the Education Committee and Resident Education Task Force for the Clinical TMS Society. \n\n\nIf you have any questions\, please email: info@clinicaltmssociety.org
URL:https://clinicaltmssociety.org/event/residents-trainee-doctors-medical-students-ctmss-education-slide-deck-transcranial-magnetic-stimulation-tms-an-introduction/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/CMTSS_Slide_Deck_for_Clinician_Residents_Thumbnail_300x150.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241021
DTEND;VALUE=DATE:20241022
DTSTAMP:20260405T182537
CREATED:20241021T132515Z
LAST-MODIFIED:20241021T132535Z
UID:1292-1729468800-1729555199@clinicaltmssociety.org
SUMMARY:On-Demand Webinars Library
DESCRIPTION:
URL:https://clinicaltmssociety.org/event/on-demand-webinars-library/
LOCATION:Zoom
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/08/CTMSS-Headers-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20241001T080000
DTEND;TZID=UTC:20241001T170000
DTSTAMP:20260405T182537
CREATED:20241016T154318Z
LAST-MODIFIED:20241017T010310Z
UID:1120-1727769600-1727802000@clinicaltmssociety.org
SUMMARY:Apples and Oranges: Comparative Effectiveness Research in TMS
DESCRIPTION:> > Register Now <<\nAlthough not labeled as such by the FDA\, TMS is considered a third line treatment by many practitioners and health insurance company policies. Earlier referral to TMS is not commonly practiced but may be non-inferior to or superior to medication switches or augmentation. Our field lacked trials that compared different modalities of treatment in parallel with TMS until recently\, which is the subject of this webinar. \nThe core aspect of this webinar will be reviewing two very recent articles that compare TMS to antidepressant medications. We will also review basic concepts of non-inferiority trials and meta-analyses. \nAt the end of the presentation\, attendees will be able to: \n\nUnderstand "head-to-head" trials and meta-analyses research.\nReview and understand recent comparative articles on TMS.\nReview and understand the current and future placement of TMS in the treatment algorithms of depression.\n\nFormat: On Demand Webinar \nCost: Members: $25 | Non-members $50 | Trainee Members FREE \nSpeaker: Mehmet Dokucu\, D\, PhD\, DFAPA \n \nDr. Dokucu is a broadly trained neuroscientist (PhD) and academic psychiatrist (MD) with expertise in Electroconvulsive Therapy\, Transcranial Magnetic Stimulation\, Consultation Liaison Psychiatry and Psycho-oncology. He was the founding director of the Transcranial Magnetic Stimulation program at Northwestern Medicine in Chicago. He is currently an Associate Professor of Psychiatry at Dartmouth Geisel School of Medicine and he currently directs the Mood Disorders and Interventional Psychiatry Program at Dartmouth Hitchcock Medical Center. \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/apples-and-oranges-comparative-effectiveness-research-in-tms-2/
LOCATION:Zoom
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/October_intro_slides.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240910
DTEND;VALUE=DATE:20240911
DTSTAMP:20260405T182537
CREATED:20241108T132217Z
LAST-MODIFIED:20241108T134039Z
UID:1560-1725926400-1726012799@clinicaltmssociety.org
SUMMARY:September 10\, 2024 Town Hall Member Meeting
DESCRIPTION:Join the Clinical TMS Society President Martha Koo\, MD\, FAPA\, FASAM\, FCTMSS\, committee co-chairs\, and other Society volunteers for an update on current activities.\nThis is your opportunity to learn more about the Society's various goals and projects.\n>>MEMBER WATCH NOW<<
URL:https://clinicaltmssociety.org/event/september-10-2024-town-hall-member-meeting/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/11/logoongray_300x150.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20240903T080000
DTEND;TZID=UTC:20240903T090000
DTSTAMP:20260405T182537
CREATED:20241017T010219Z
LAST-MODIFIED:20241017T010328Z
UID:1177-1725350400-1725354000@clinicaltmssociety.org
SUMMARY:Stimulating for Hope: Transcranial Magnetic Stimulation for Patients at Risk for Suicide
DESCRIPTION:> > Register Now <<\n\nThe United States is in the midst of a crisis of suicide\, and TMS providers often must confront this directly. In this presentation\, Dr. Philip will provide a brief overview of the existing TMS protocols used to reduce suicidal ideation\, reviewing their efficacy and also burden of administration. He will describe an ongoing clinical trial combining TMS plus psychotherapy for PTSD\, and outline his own clinical approach to treating suicidal patients\, so that attendees can consider how they can address this critically important issue. \nAt the end of the presentation\, attendees will be able to: \n\nDescribe various evidence-based TMS parameters to treating patients at higher suicide risk.\nDemonstrate understanding of the interaction (or lack thereof) between changes in depression and suicidal ideation during TMS.\nDiscuss future TMS options in high risk patients.\n\nFormat: On-Demand Webinar \nCost: Members: $25 | Non-members $50 | Student Members FREE \nSpeaker: Noah S. Philip\, MD \n \nDr. Philip is a Professor of Psychiatry and Human Behavior at the Alpert Medical School of Brown University. He is the founding Section Chief of Psychiatric Neuromodulation at VA Providence\, and is Lead for Mental Health Research at the VA RR&D Center for Neurorestoration and Neurotechnology. \nDr. Philip received his BSc from McGill University and his MD from Albany Medical College where he graduated AOA and with a Distinction in the Study of Biomedical Ethics. He completed his psychiatry residency training at Brown University\, followed by T32 and Neuromodulation Fellowships at Brown. \nDr. Philip’s laboratory uses a precision approach to new and emerging technologies\, with the goal to understand and treat posttraumatic stress disorder\, major depression\, and suicidality. His research has been featured in JAMA Psychiatry\, American Journal of Psychiatry\, Biological Psychiatry\, and the National Neuroscience Curriculum Initiative (tDCS+Virtual Reality for PTSD). He is currently conducting an NIMH-funded cooperative study to perform a first-in-human study investigating MRI-guided low intensity focused ultrasound for depression and anxiety (U01 MH123427). \nDr. Philip has received awards and recognition from the American Psychiatric Association\, Society for Biological Psychiatry\, American College of Neuropsychopharmacology\, and others. He has been funded through grants from the VA (Rehabilitation\, Clinical Science\, and Health Services R&D)\, NIMH\, NIDA\, Department of Defense\, and through industry and small-business collaborations. He is active in several national organizations\, including SOBP and ACNP\, and is a past President of the Psychiatric Research Society. \nDr. Philip plays a significant training and mentoring role at Brown\, where he is Associate Director of the NIMH R25 psychiatry resident research training program\, and serves as a mentor through national organizations such as the Career Development Institute for Psychiatry. He is committed to action to improve diversity\, equity\, inclusion\, and belonging. \n\n> > Register Now <<
URL:https://clinicaltmssociety.org/event/stimulating-for-hope-transcranial-magnetic-stimulation-for-patients-at-risk-for-suicide/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/September_intro_slides-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20240806T200000
DTEND;TZID=UTC:20240806T210000
DTSTAMP:20260405T182537
CREATED:20240731T205123Z
LAST-MODIFIED:20241017T010542Z
UID:405-1722974400-1722978000@clinicaltmssociety.org
SUMMARY:What Does a TMS Doctor Need to Know About Brain Networks?
DESCRIPTION:> > Register Now <<\nNetwork neuroscience is becoming increasingly relevant to the clinical practice of TMS\, but it is a large and complicated field that is impossible for a clinician to follow comprehensively. This lecture will provide a basic foundation of brain networks and describe general principles for how to recognize when a new development in this field is clinically useful. \nAt the end of this presentation participants will: \n\nDefine specific brain networks currently involved in TMS targeting.\nAppraise new network-based TMS targets to determine when they are ready for clinical practice.\nRecognize which brain network studies are not clinically useful yet.\n\nOne Hour CME Credit Available \nFormat: On-Demand Webinar \nCost: Members: $25 | Non-members $50 | Student Members FREE \nSpeaker: Shan H. Siddiqi\, MD \n \nDr. Siddiqi is an assistant professor of psychiatry at Harvard Medical School\, a neuropsychiatrist at Brigham & Women’s Hospital\, and director of psychiatric neuromodulation research for the Center for Brain Circuit Therapeutics. His research is focused on causal mapping of human brain function and dysfunction. Using techniques such as functional MRI\, his lab maps brain circuits to link brain lesions and brain stimulation sites that can modify different psychiatric symptoms. These circuits can then be targeted with treatments such as TMS to alleviate symptoms in psychiatric disorders. His work has been recognized with multiple awards from the National Institute of Mental Health\, the Brain & Behavior Research Foundation\, the American Neuropsychiatric Association\, the American College of Neuropsychopharmacology\, Harvard Medical School\, and many others. \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/how-to-understand-the-exploding-evidence-on-new-circuit-based-tms-targets/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/07/August_Thumbnail.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20240702T200000
DTEND;TZID=UTC:20240702T210000
DTSTAMP:20260405T182537
CREATED:20241022T125801Z
LAST-MODIFIED:20241022T125801Z
UID:1298-1719950400-1719954000@clinicaltmssociety.org
SUMMARY:What’s the Secret Recipe? Treating Depression with TMS in the Era of Accelerated Protocols and Functional MRI Targeting
DESCRIPTION:Methods for enhancing the antidepressant effects and treatment efficiency of transcranial magnetic stimulation have advanced rapidly in the past several years\, with new FDA-cleared protocols and promising early data. Dr. Trapp will discuss the evidence for various TMS optimization procedures with a focus on trying to understand the “secret recipe” for delivery of the most efficacious TMS treatment protocol. \nDuring this presentation participants will: \n\nDiscuss current methods and considerations for TMS targeting of the DLPFC for depression treatment.\nDiscuss current evidence for dose-response effects and accelerated TMS protocols for depression.\nReview methods and data for optimizing the antidepressant effects of TMS.\n\nOne Hour CME Credit Available \nFormat: Webinar \nCost: Members: $25 | Non-members $50 | Student Members FREE \nSpeaker: Nicholas T. Trapp\, MD \n \nDr. Trapp is an Assistant Professor of Psychiatry at the University of Iowa\, where he is the Director of the Interventional Psychiatry Program and the Neuropsychiatry Clinic.  He completed psychiatry residency at Washington University in St. Louis\, followed by post-doctoral fellowship in neurostimulation and neuroimaging at the University of Iowa and behavioral neurology/neuropsychiatry at Stanford University. His research focuses on the targeting\, application\, and optimization of neuromodulation therapies for the treatment of psychiatric conditions. Projects have included novel TMS clinical trials\, mechanistic TMS studies\, and lesion-network mapping of psychiatric symptoms to identify candidate brain stimulation targets. He also leads the TMS for Depression Consensus Recommendations Work Group as part of the National Network of Depression Centers Neuromodulation Task Group and serves on the Clinical TMS Society Research Committee. Clinically Dr. Trapp evaluates patients for TMS\, ECT\, DBS\, VNS\, and esketamine.  He has received Career Development Awards from the National Institutes of Mental Health and the American Neuropsychiatric Association\, as well as a Young Investigator Award from the Brain and Behavior Research Foundation. His current research funding is to study the electrophysiologic effects of TMS in epilepsy patients with intracranial recording electrodes.
URL:https://clinicaltmssociety.org/event/whats-the-secret-recipe-treating-depression-with-tms-in-the-era-of-accelerated-protocols-and-functional-mri-targeting/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/July_Thumbnail.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20240507T170000
DTEND;TZID=UTC:20240507T180000
DTSTAMP:20260405T182537
CREATED:20240729T045056Z
LAST-MODIFIED:20241017T011001Z
UID:295-1715101200-1715104800@clinicaltmssociety.org
SUMMARY:The Unique Case of Bipolar Depression and Transcranial Magnetic Stimulation
DESCRIPTION:> > Register Now <<\nThere are few level 1 evidence based treatments for bipolar depression\, and when these are either ineffective or poorly tolerated alternative non-pharmacological treatments are required. Non-invasive neurostimulation\, in particular transcranial magnetic stimulation\, is a treatment option for difficult to treat depression that is of interest in bipolar depression. In 2020\, the FDA granted breakthrough designation for TMS for bipolar depression\, however if it does receive approval it remains to be determined where TMS belongs in the bipolar depression algorithm. Here\, we will review the management of bipolar depression\, and review the peer reviewed literature using TMS to treat bipolar depression. In particular\, the conflicting data will be contextualized within the unique biological and pharmacological constraints that characterize bipolar disorder. \nAt the end of this presentation participants will: \n\nUnderstand the current management of bipolar depression.\nReview the clinical trial and open label literature using TMS to treat bipolar depression.\nAppreciate the complex interplay between biology and pharmacology that makes TMS in bipolar disorder unique.\n\n1 CME Credit Available \nFormat: Webinar \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSpeaker: Alexander McGirr\, MD\, PhD\, FRCPC \nAlexander McGirr received his MSc in neuroscience at McGill University under Dr. Gustavo Turecki before pursuing medical school at the University of Toronto. There\, in addition to medical studies he pursued basic science training under Dr. John Roder. His research track psychiatry residency at the University of British Columbia\, where his clinical research in mood disorders was under Drs. Lam and Yatham\, included a contemporaneous PhD in Neuroscience under Dr. Timothy Murphy. His independent research includes two fronts: 1) a human research program that is both pre-clinical and clinical using non-invasive brain stimulation to probe and treat neuropsychiatric illness\, and 2) a basic science program using animal models and next gen technologies for circuit dissection and to understand how risk factors related to neuropsychiatric illness change neural circuitry in an effort to inform treatments in humans. \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/the-unique-case-of-bipolar-depression-and-transcranial-magnetic-stimulation/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/07/May.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20240402T080000
DTEND;TZID=UTC:20240402T210000
DTSTAMP:20260405T182537
CREATED:20241017T011237Z
LAST-MODIFIED:20241021T200002Z
UID:1184-1712044800-1712091600@clinicaltmssociety.org
SUMMARY:Electroconvulsive Therapy: How to Make a Highly Effective Treatment More Acceptable
DESCRIPTION:> > Register Now <<\nElectroconvulsive therapy (ECT) is a highly effective treatment for major depression.  However\, it is underused due to stigma and concern over its side effects on memory.  This webinar will describe the history of ECT including its many improvements over more than 80 years. This will be followed by a presentation of recent research that aims to make ECT more acceptable by minimizing its side effects on memory through better understanding of the mechanisms of its therapeutic effect on depression and its adverse effects on memory. \nAt the end of this presentation participants will: \n\nBe familiar with the history of ECT including its improvements over more than 80 years.\nBe aware of the therapeutic effect of ECT on major depression and the adverse effect of ECT on memory.\nLearn of new research into the mechanisms of the therapeutic and adverse effects of ECT that aims to make ECT more acceptable by minimizing its side effects on memory.\n\n1 Hour CME Credit Available \nFormat: Webinar \nCost: Members: $25 | Non-members $50 | Student Members FREE \nSpeaker: William T. Regenold\, MDCM \n \nWilliam T. Regenold\, MDCM is a board certified general and geriatric psychiatrist.  He is a Senior Research Physician and the Medical Director of the Noninvasive Neuromodulation Unit (NNU) in the Experimental Therapeutics and Pathophysiology Branch of the National Institute of Mental Health (NIMH).  At the NIMH\, he collaborates with a research team investigating electroconvulsive therapy and transcranial magnetic stimulation\, primarily in the treatment of major depression. Dr. Regenold studied medicine at McGill University in Montreal.  He trained in Medicine\, Neurology and Psychiatry at the Johns Hopkins Bayview Medical Center in Baltimore and in Psychiatry and Old Age Psychiatry at the Johns Hopkins Hospital in Baltimore and the Maudsley Hospital in London. Prior to joining the NIMH\, he was at the University of Maryland Department of Psychiatry where he was Director of the Division of Geriatric Psychiatry\, the Adult Inpatient Service\, and the Electroconvulsive Therapy Service.  His research at the University of Maryland focused on mood disorder pathophysiology and electroconvulsive therapy. \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/electroconvulsive-therapy-how-to-make-a-highly-effective-treatment-more-acceptable/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/April_Grand_Rounds.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20240305T080000
DTEND;TZID=UTC:20240305T210000
DTSTAMP:20260405T182537
CREATED:20241017T011402Z
LAST-MODIFIED:20241021T200245Z
UID:1189-1709625600-1709672400@clinicaltmssociety.org
SUMMARY:Research and Clinical Applications of TMS in Pediatric and Neurodevelopmental Populations
DESCRIPTION:> > Register Now <<\nThe CDC currently estimates that nearly 1 in 5 children have a developmental or psychiatric disorder; yet evidence-based\, targeted treatments for these disorders are lacking. \nTaking an Experimental Therapeutics approach\, the research that will be discussed aims to understand the mechanisms that contribute to dysfunctional development of neural systems associated with symptoms of pediatric psychiatric and neurodevelopmental disorders utilizing neuroimaging and neurophysiological tools combined with transcranial magnetic stimulation interventions. The ultimate goal of the research that will be discussed is to inform the development of novel targeted device-based treatment strategies. Though there is much promise for these targeted device-based interventions\, data on the safety and efficacy of these interventions in pediatric and neurodevelopmental populations is limited. The current state of the research will be reviewed and future directions for the field will be discussed. \nAt the end of this presentation participants will be able to: \n\nReview the findings of studies using TMS to probe physiology in autism spectrum disorder (ASD).\nDescribe how TMS can be used to induce long-term changes in brain network functioning and potentially treat pediatric neuropsychiatric and behavioral disorders.\nIdentify potential network targets where applying TMS may be effective for reducing transdiagnostic symptom domains commonly seen in neuropsychiatric and behavioral disorders.\n\n1 Hour CME Credit Available \nFormat: Live Webinar \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSpeaker: Lindsay Oberman\, PhD \n \nDr. Lindsay Oberman received her PhD from UCSD in Experimental Psychology in 2007. Since that time\, she has published over 60 peer-reviewed articles. She has gained international attention for pioneering the use of Repetitive Transcranial Magnetic Stimulation (rTMS) in complex neurodevelopmental and neuropsychiatric disorders including autism\, mood disorders\, and traumatic brain injury. Dr. Oberman’s research involves the use of an experimental therapeutics approach applying neuroimaging and neurophysiological measures to identify dysfunctional neural circuitry associated with specific transdiagnostic behavioral domains such as mood regulation\, sensory processing\, social cognition\, and executive functioning across disorders. In doing so\, she is able to develop novel individualized rTMS treatment protocols that are informed by functional brain network organization. She is currently a Staff Scientist and Directs the Developmental Clinical Neurophysiology and Neurostimulation Research Program within the National Institute of Mental Health Intramural Research Program. \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/research-and-clinical-applications-of-tms-in-pediatric-and-neurodevelopmental-populations-2/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/March_Thumbnail.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20240206T190000
DTEND;TZID=America/Chicago:20240206T200000
DTSTAMP:20260405T182537
CREATED:20240730T004806Z
LAST-MODIFIED:20241017T011442Z
UID:318-1707246000-1707249600@clinicaltmssociety.org
SUMMARY:Controlling Brain State Variability to Optimize rTMS Efficacy
DESCRIPTION:> > Register Now <<\nThe Clinical TMS Society presents this installment of our Grand Rounds Webinar Series: Controlling Brain State Variability to Optimize rTMS Efficacy featuring Speaker: Lysianne Beynel\, PhD \nIn this presentation\, we will explore the pivotal role of brain state variability in influencing basic TMS outcomes like MEP and phosphenes. We will then focus on some clinical applications that used control of state-dependency as a proof of principle. Finally\, in a demonstration of a specific case of state-dependency control\, we will uncover the potential synergy between rTMS and cognitive therapy in\nimproving depression treatment\, as a way to pave the way for more personalized and effective therapies. \nAt the end of this presentation participants will be able to:\n• Demonstrate how varying brain states affect basic TMS measures like motor\nevoked potentials (MEPs) and phosphenes.\n• Evaluate the impact of controlling brain state on improving rTMS outcomes as\na proof of principle.\n• Examine the potential benefits of combining rTMS with cognitive therapy for\ntreating depression in this context. \nTake advantage of our live Q&A session at the conclusion of the webinar! \n1 Hour CME Credit available \nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\n \nSpeaker: Lysianne Beynel\, PhD \nDr. Beynel completed her PhD at University Grenoble Alpes in France where she\ninvestigated the effects of transcranial magnetic stimulation (TMS) on bipolar\ndisorders. She then moved to Duke University for her post-doc work\, where she\ninvestigated the use of rTMS in improving working memory in older adults. Her\nresearch\, at that time\, was mainly focused on the effects of ‘online’ TMS\, i.e.\, applying\nstimulation while participants were performing a task\, as a potential means to further\nengage the stimulated network and produce stronger effect. She is now a Research\nFellow at the NonInvasive Neuromodulation Unit (NNU) in the Experimental\nTherapeutics and Pathophysiology Branch of the National Institute of Mental Health\,\nwhere she is combines two of these skill sets to apply TMS during cognitive therapy to\nimprove outcomes in depressive disorders. Dr. Beynel is also exploring the potential\nof combining real-time fMRI neurofeedback with rTMS to achieve more precise control\nover brain state. \n\n> > Register Now <<
URL:https://clinicaltmssociety.org/event/controlling-brain-state-variability-to-optimize-rtms-efficacy/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/07/February_thumbnail_2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20240109T080000
DTEND;TZID=UTC:20240109T210000
DTSTAMP:20260405T182537
CREATED:20240815T015312Z
LAST-MODIFIED:20241021T200438Z
UID:847-1704787200-1704834000@clinicaltmssociety.org
SUMMARY:TMS Documentation: Expert Perspectives
DESCRIPTION:> > Register Now <<\nThe CTMSS Insurance Committee presents: "TMS Documentation: Expert Perspectives". In this panel discussion\, we will discuss the range of approaches when it comes to documenting TMS sessions. We will also explore how the documentation serves multiple purposes for different audiences: clinical and administrative staff\, patients\, payers\, and the court. \nAt the end of this presentation\, participants will be able to: \n\ndescribe the core elements of a TMS procedure note in order to adequately convey clinical information to others involved in the care of a patient.\nunderstand the range of approaches to documentation of TMS sessions and the benefits and limitations of each approach.\ndevelop an approach to documentation of TMS sessions for your practice that meets the expectations of relevant insurance plans and malpractice carriers.\n\nThis Grand Rounds Webinar will highly encourage audience participation! \n1 Hour CME Credit available \nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\n  \n\nPanelists:\nSam Huber\, MD\, MS \n \nDr. Huber is an experienced physician executive and clinical psychiatrist. He holds degrees from the University of Rochester\, University of Rochester School of Medicine\, and the Dartmouth Institute for Health Policy and Clinical Practice. He trained at Washington University in St. Louis and the White River Junction Vermont VA Medical Center. He has served as Medical Director for Inpatient Psychiatry\, Medical Director for Interventional Psychiatry\, and Associate Quality Officer at the University of Rochester Medical Center\, Associate CMO for Patient Safety and Quality at Rochester Regional Health (Rochester\, NY)\, and Chief Medical Officer for MultiCare Behavioral Health-MultiCare Health System (Tacoma\, WA). He has clinical experience across the spectrum of acute services including short and long-term inpatient\, emergency psychiatry\, consultation/integrated care\, neuromodulation (ECT\, TMS) and adult ambulatory psychiatry. As Medical Director for Interventional Psychiatry\, Dr. Huber partnered with multiple divisions and stakeholders to sustain a margin-positive ECT service and launch the Rochester region’s first TMS service within a health system. \nShelly Lahn\, MBA \n \nShelly Lahn is the CEO of Neuro Wellness TMS Centers of America where they specialize in transcranial magnetic stimulation (TMS). \n\nCTMSS Insurance Committee member\nNational Ketamine Task Force member\nOwner/Operator/Founder of Neuro Wellness Centers of America using Apollo TMS Machines\n\nRebecca Allen\, MD\, MPH \n \nDr. Allen graduated with a B.A. in Psychology with honors from Stanford University. She attended Oregon Health and Science University for medical school where she also earned a Masters of Public Health in biostatistics and epidemiology. She completed psychiatry residency at the Harvard Longwood Psychiatry Residency Training Program\, a joint program between Brigham and Women’s Hospital\, Beth Israel Deaconess Medical Center\, and Massachusetts Mental Health Center. She served as Chief Resident of the psychiatry consult service at Beth Israel Deaconess Medical Center. She then went on to complete a 2-year fellowship in Neuropsychiatry at Brigham and Women’s Hospital. She has participated in research on sleep and memory consolidation\, quality of life in multiple sclerosis\, efficacy of different TMS protocols\, EEG biomarkers of TMS response\, the RECOVER VNS trial\, and other projects. She has authored several papers. \nModerator:\nCarlene MacMillan\, MD \n \nDr. MacMillan is the Chief Medical officer at Osmind. Osmind is a technology platform that helps clinicians who provide breakthrough mental health treatments track outcomes and document interventions. She is the Co-Chair of the Clinical TMS Society Insurance Committee and on the Board of Directors of the Clinical TMS Society. She participates in neuromodulation clinical trials and post-marketing research. She completed her medical training at Harvard medical school and her adult psychiatry residency and child psychiatry fellowship at Massachusetts General Hospital and McLean Hospital. \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/tms-documentation-expert-perspectives/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/08/January_24_GRW_Event_Thumbnail.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20231205T200000
DTEND;TZID=UTC:20231205T210000
DTSTAMP:20260405T182537
CREATED:20240731T212112Z
LAST-MODIFIED:20241017T011909Z
UID:413-1701806400-1701810000@clinicaltmssociety.org
SUMMARY:Precision Organizational and Functional Estimates for TMS Targeting
DESCRIPTION:> > Register Now <<\nYou’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Precision Organizational and Functional Estimates for TMS Targeting featuring Dr. Mark Eldaief! \nNetwork models are increasingly invoked to characterize the neurobiological underpinnings of mental illnesses. Dysfunction within specific networks (e.g.\, the default\, salience and control networks) promotes the formation of specific symptoms. This suggests an opportunity to treat specific depressive symptoms by modulating specific circuits with transcranial magnetic stimulation (TMS). In this talk\, I will review our project which uses precision MRI methods to delineate cortical networks in the individual at high resolution and to then stimulate specific networks in separate sessions with TMS. We will then survey the differential impact of network-specific stimulation with REST-BOLD and TASK-BOLD imaging as well as with validated state-based questionnaires and brief neuropsychological tests. This work will facilitate individualized neuromodulation approaches based on network topography. This will pollinate large-scale clinical trials assessing the effects of differential circuit modulation. It will also illuminate circuit-construct relationships across neuropsychiatric disorders. \nAt the end of this presentation participants will be able to: \n\ndescribe the network basis of specific psychopathological symptoms in depression.\nidentify the use of precision MRI to define cortical networks in the individual.\nlist the methods of applying TMS to specific networks in the individual to modulate specific symptom domains.\n\n1 Hour CME Credit available \nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKERS: \nMark Eldaief\, MD\n \nDr. Eldaief attended medical school at Columbia University. Following this\, he did a combined residency in Neurology and Psychiatry at Columbia and a Research Fellowship in Cognitive Neurology at the Beth Israel Deaconess Medical Center. He is now an Assistant Professor of Neurology at Harvard Medical School and is a staff neurologist and psychiatrist at the Massachusetts General Hospital. \n\n  \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/precision-organizational-and-functional-estimates-for-tms-targeting/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/07/December_23_GRW_Event_Thumbnail.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20231107T200000
DTEND;TZID=UTC:20231107T210000
DTSTAMP:20260405T182537
CREATED:20240730T012022Z
LAST-MODIFIED:20241017T011945Z
UID:323-1699387200-1699390800@clinicaltmssociety.org
SUMMARY:Vagus Nerve Stimulation: What Do We Have When All Treatments Have Failed?
DESCRIPTION:> > Register Now <<\nYou’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Vagus Nerve Stimulation: What Do We Have When All Treatments Have Failed?  featuring Dr. Scott Aaronson! \nDespite compelling evidence for efficacy\, vagus nerve stimulation has languished due to problems with the design of two randomized clinical trials which led to a non coverage determination (NCD) made by in Centers for Medicare and Medicaid (CMS) in 2007.  After a seminal comparative observational study was published in 2017\, CMS agreed to rescind its NCD and agreed to fund a coverage with evidence  development study for up to 1000 participants with either unipolar or bipolar depression.  The unipolar arm of the one year study will be completed in the Spring of 2024.  In preparation for the potential clinical availability of VNS\, we will review the proposed mechanism of action\, identify appropriate candidates\, review the existing outcomes data and discuss the advantages and disadvantages of this unique albeit invasive treatment approach for the most severely treatment resistant depressions. \nAt the end of this presentation participants will be able to: \n\n describe the proposed mechanism of action for VNS\n identify potential candidates for the use of VNS\n list the most frequent adverse events found in the use of VNS\n\n1 Hour CME Credit available \nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKERS: \nScott T. Aaronson\, MD\, DLLAPA\, FCTMSS\n \nDr. Scott Aaronson is a thought leader in the areas of biological psychiatry\, diagnosis\, and the integration of somatic and psychological therapies. He is an adjunct professor of psychiatry at the University of Maryland School of Medicine\, distinguished life fellow of the American Psychiatric Association\, and is a fellow of the American College of Psychiatrists. Dr. Aaronson also serves/served on the boards of the American Society of Clinical Psychopharmacology and the Clinical TMS Society. \nIn addition to his work at The Retreat\, Dr. Aaronson is the director of clinical research programs at Sheppard Pratt\, where he is the principal investigator for multiple studies on the development of therapies for mood and anxiety disorders. He has particularly been involved with the development of new strategies to alleviate the symptoms in treatment resistant mood disorders\, and has published numerous articles on his research including pivotal studies in the use of devices—Transcranial Magnetic Stimulation (TMS) and Vagus Nerve Stimulation (VNS)—in the treatment of severe refractory mood disorders. Most recently\, he was named the Chief Science Officer of the Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics\, focused on the development of uses for psychedelic medications across the spectrum of psychiatric illness. \n  \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/vagus-nerve-stimulation-what-do-we-have-when-all-treatments-have-failed/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/07/November_7_GRWS_Event_Thumbnail_V3.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20231003T200000
DTEND;TZID=UTC:20231003T210000
DTSTAMP:20260405T182537
CREATED:20240731T204319Z
LAST-MODIFIED:20241017T012013Z
UID:403-1696363200-1696366800@clinicaltmssociety.org
SUMMARY:Neuromodulation for the Traumatized Brain: Modulating Dysfunctional Neural Networks in PTSD
DESCRIPTION:> > Register Now <<\nYou’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Neuromodulation for the Traumatized Brain: Modulating Dysfunctional Neural Networks in PTSD  featuring Dr. Sandeep Vaishnavi! In this presentation\, Sandeep Vaishnavi\, MD\, PhD will discuss the neural networks involved in stress and fear responses thought to be dysfunctional in PTSD.  He will review nodes in these networks that could be modulated by TMS.  He will then review the current state of evidence of TMS for PTSD\, including figure-of-8 coil\, H-coil\, and theta burst studies. At the end of this presentation participants will be able to: \n\n describe the neural networks thought to be dysfunctional in PTSD\n explain the strategies used to modulate nodes in these dysfunctional networks\n understand the current state of evidence for use of neuromodulation to improve PTSD symptoms\n\n1 Hour CME Credit available Format: On-Demand Cost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKERS: \nSandeep Vaishnavi\, MD\, PhD\nDr. Sandeep Vaishnavi is a faculty network member of the Duke Institute for Brain Sciences (DIBS) and an adjunct associate in the Department of Medicine at Duke University.  He is the president of the Center for Neuropsychiatry and Brain Stimulation (CNBS)\, an ARC Health practice.  He is the co-author of the books\, The Traumatized Brain:  A Family Guide to Understanding Mood\, Memory\, and Behavior after Brain Injury and Healing the Traumatized Brain:  Coping after Concussion and other Brain Injuries. \n\n  \n  \n  \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/neuromodulation-for-the-traumatized-brain-modulating-dysfunctional-neural-networks-in-ptsd/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/07/October_23_GRW_Event_Thumbnail.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20230905T180000
DTEND;TZID=UTC:20230905T190000
DTSTAMP:20260405T182537
CREATED:20240731T195314Z
LAST-MODIFIED:20241017T012055Z
UID:393-1693936800-1693940400@clinicaltmssociety.org
SUMMARY:The Great Potential of QPS for Optimizing rTMS Outcomes
DESCRIPTION:> > Register Now <<\nYou’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: The Great Potential of QPS for Optimizing rTMS Outcomes featuring Dr. Amanda Tiksnadi! \nTranscranial magnetic stimulation (TMS) has been known as a novel technique to modulate brain neuronal activity non-invasively. The magnitude and direction of modulatory effects of rTMS critically depend on the chosen protocol variables\, e.g. stimulation intensity\, frequency\, train length\, intertrain-interval\, total number of magnetic pulse\, as well as the coil configuration\, current direction\, pulse waveform\, and position of the coil with respect to the cortex. Several methods have been validated to increase the efficacy of rTMS\, i.e.\, iTBS and cTBS. This presentation will cover a new emerging method of QPS (Quadripulse Stimulation) that has shown higher efficacy in motor cortical plasticity than the previous method. This method may solve some of the major obstacles in achieving treatment efficacy for “rTMS-resistant” patients. \nAt the end of this presentation\, participants will be able to: \n\n Describe the basics of Quadripulse Stimulation\n Explain the efficacy of Quadripulse Stimulation on motor cortical plasticity\n Discuss the potential of Quadripulse Stimulation for optimizing rTMS outcomes\n\n1 Hour CME Credit available \nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKERS: \nAmanda Tiksnadi\, MD\, PhD\n \nDr. Amanda Tiksnadi is a neurologist at the Neurology Department\, Faculty of Medicine\, Universitas Indonesia. Her special interests are movement disorders\, neurorestoration & neuroengineering\, and non-invasive brain stimulation. \nDr. Tiksnadi is currently Chief of Neurorestoration Division\, Dept. of Neurology\, Fac. of Med. at Universitas Indonesia\, Chief of Movement Disorder Division\, Dept. of Neurology\, Fac. of Med. at Universitas Indonesia\, and Chief of Brain Stimulation and Neurorestoration Lab at Cipto Mangunkusumo Hospital\, Jakarta as well as Universitas Indonesia Hospital\, Depok. \n\n  \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/the-great-potential-of-qps-for-optimizing-rtms-outcomes/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/07/September_23_GRW_Event_Thumbnail.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20230801T200000
DTEND;TZID=UTC:20230801T200000
DTSTAMP:20260405T182537
CREATED:20240731T212757Z
LAST-MODIFIED:20241017T012125Z
UID:418-1690920000-1690920000@clinicaltmssociety.org
SUMMARY:Anatomy of Theta Burst
DESCRIPTION:> > Register Now <<\nYou’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Anatomy of Theta Burst featuring Dr. Bob Sammons! \nThe presentation will review the Anatomy of Theta Burst. Theta burst is gaining popularity in both research and clinical practice but the fundamental differences with rTMS make it hard for many clinicians to understand. This presentation is designed to facilitate the understanding of and ability to explain theta burst in detail. After a brief review of how theta burst was discovered\, the focus shifts to its clinical usage and advanced protocols. A review of continuous theta burst concludes the presentation. \nTake advantage of our Q&A portion at the conclusion of the webinar! \nAt the end of this presentation participants will be able to: \n\n understand why does the definition of theta burst contain both 5 Hz and 50 Hz\n explain why theta burst was originally thought to be stronger and faster than rTMS\n discuss how theta burst originated\n\n1 Hour CME Credit available \nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKERS: \nBob Sammons\, MD\, PhD\, FCTMSS\n \nDr. Bob Sammons received a bachelors and master’s degree from Auburn University\, a PhD in clinical psychology from the University of North Carolina at Greensboro\, and a medical degree from the University of North Carolina at Chapel Hill. He did a residency in psychiatry at the University of Virginia as well as a forensic psychiatry fellowship. While a Captain in the Air Force he helped set up and run the treatment phase of the Air Force Drug Treatment program in 1971. He practiced adult psychiatry in Grand Junction for 30+ years. He received training in Transcranial Magnetic Stimulation in 2006 from Dr. Alvaro Pascual-Leone\, from Dr. Mark George in 2017 and returned to Harvard for Dr. Pascual-Leone’s intensive course in TMS in 2018. He is Medical Director for TMS Solutions with fourteen TMS offices in various locations in the West. He is on the national Clinical TMS Society Board of Directors\, sits on three national committees and is Chairman of the 2022 Annual Meeting. He has been known to cook a little BBQ. \n  \n  \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/anatomy-of-theta-burst/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/07/August_23_GRW_Event_Thumbnail.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20230711T180000
DTEND;TZID=UTC:20230711T190000
DTSTAMP:20260405T182537
CREATED:20240731T202715Z
LAST-MODIFIED:20241017T012733Z
UID:395-1689098400-1689102000@clinicaltmssociety.org
SUMMARY:Transcranial Magnetic Stimulation and Neuroplasticity
DESCRIPTION:> > Register Now <<\nYou're invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Transcranial Magnetic Stimulation and Neuroplasticity\, featuring Dr. Sabrina Segal! \nThe field of transcranial magnetic stimulation is evolving with novel protocols to treat depression\, and explorative studies to target other therapeutic avenues for mental health. This presentation will review the neuroplastic mechanisms that underly the therapeutic effects of TMS and explain the role of neuroplasticity in TMS-treated psychiatric and neurological conditions. This talk will also examine novel explorations for TMS and memory. \nDon't miss out on our Q&A portion of the webinar! \nAt the end of this presentation\, participants will be able to identify and understand the following:  \n\nIdentify the neuroplastic mechanisms that underly the therapeutic effects of TMS\nDescribe the role of TMS and neuroplasticity in psychiatric and neurological conditions\nExplore the therapeutic potential for TMS on neuroplastic mechanisms that underly memory\n\nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKER: \nSabrina Segal\, PhD\nDr. Segal earned her Ph.D. in Neurobiology and Behavior from the University of California\, Irvine in 2010 and her research on exercise and memory received international recognition in 2012. She completed a postdoctoral fellowship at UC Irvine\, UC Irvine Medical School Department of Anesthesiology and Children’s Hospital of Orange County (CHOC) from 2010-2014. She was a Research Professor at Arizona State University from 2014-2016\, and has taught courses in biology\, psychology\, and neurobiology at colleges and military bases in California\, Colorado and Arizona. Her research has focused on memory consolidation and enhancement via neuroplastic mechanisms. \nShe is extremely passionate about neuroscience research\, the application of research to clinical practice\, and improving education for mental health providers. In 2016\, Dr. Segal joined the Neuroscience Education Institute\, a continuing medical education company founded by world-renowned psychiatrist Dr. Stephen Stahl\, where she developed high quality educational material based on the most current neuroscience research for mental health providers globally. She specialized in neurostimulation techniques like transcranial magnetic stimulation (TMS). Dr. Segal has published many scientific peer-reviewed journal articles\, and several books. She is the author of: Beyond the Impact: An Update on the Assessment\, Prevention\, and Treatment of Neuropsychiatric Sequelae Associated with Traumatic Brain Injury and Stahl’s Illustrated: Treatments for Mood Disorders. She was also the host for the Neuroscience Education Institute podcast\, where she published nearly 200 episodes on psychiatry and related mental health topics. \nShe is most passionate about the clinical application of TMS research\, and she recently collaborated on TMS research with Dr. Robert Sammons\, which was presented as an abstract poster at the CTMSS meeting in May 2023.  Dr. Segal is currently Director of Research at Family Care Center\, a multi-state integrative mental health clinic that combines therapy\, medication management and transcranial magnetic stimulation. \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/transcranial-magnetic-stimulation-and-neuroplasticity/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/07/July_23_GRWS_Slide_Banner_Full.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20230606T200000
DTEND;TZID=UTC:20230606T210000
DTSTAMP:20260405T182537
CREATED:20241022T130724Z
LAST-MODIFIED:20241022T130724Z
UID:1300-1686081600-1686085200@clinicaltmssociety.org
SUMMARY:How to Understand the Exploding Evidence on New Circuit-Based TMS Targets
DESCRIPTION:You're invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: How to Understand the Exploding Evidence on New Circuit-Based TMS Targets\, featuring Shan Siddiqi\, MD! \nWe are currently in the midst of a rapid growth of evidence on new circuit-based TMS targets. This leaves the clinician with a challenging conundrum. When is the evidence strong enough to use a target clinically? When there is no clinical trial\, can we learn from cohort studies? How valuable are lesion studies or functional neuroimaging studies? And how do I bring together all of this information to give my patient the best possible treatment? Fortunately\, we don’t need to reinvent the wheel - there are several guidelines on how to weigh evidence across medicine. In this session\, we will discuss how to apply these guidelines to circuit-targeted brain stimulation. \nTake advantage of our Q&A portion of the webinar! \nAt the end of this presentation\, participants will be able to identify and understand the following:  \n\nDescribe emerging approaches for targeting brain circuits with TMS\nAppraise evidence for emerging circuit-based treatment targets\nIdentify treatment targets that have strong evidence-based support\n\nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKER: \nShan Siddiqi\, MD \n \nDr. Siddiqi’s research is focused on mapping new TMS targets for neuropsychiatric disorders based on causal mapping of human brain function and dysfunction. Using techniques such as functional connectivity MRI\, his lab maps brain circuits to link brain lesions and brain stimulation sites that can modify different psychiatric symptoms. These circuits can then be targeted with treatments such as transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS) to alleviate psychiatric symptoms. His work has been recognized with multiple awards from the Brain & Behavior Research Foundation\, the American Neuropsychiatric Association\, the American College of Neuropsychopharmacology\, Harvard Medical School\, and many others.
URL:https://clinicaltmssociety.org/event/how-to-understand-the-exploding-evidence-on-new-circuit-based-tms-targets-2/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/June_23_GRWS_Slide_Banner_300x150.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20230404T200000
DTEND;TZID=UTC:20230404T210000
DTSTAMP:20260405T182537
CREATED:20241022T131421Z
LAST-MODIFIED:20241022T131421Z
UID:1302-1680638400-1680642000@clinicaltmssociety.org
SUMMARY:Deep TMS with the H7 Coil over the Dorsomedial PFC
DESCRIPTION:You're invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Deep TMS with the H7 Coil over the dorsomedial PFC\, featuring Aron Tendler\, MD! \nThe presentation will explain the physical capabilities and limitations of the current commercially available coils and how they relate to areas of stimulation. This presentation will also explain the level of available evidence with the H7 for OCD\, MDD\, Alcohol Use Disorder and cocaine. \nTake advantage of our Q&A portion at the conclusion of the webinar! \nAt the end of this presentation\, participants will be able to identify and understand the following:  \n\nPhysical capabilities of the commercially available coils using electrical field measurements and simulations\nEvidence for H7 and other coils for the treatment of OCD\nEvidence for H7 and other coils for the treatment of MDD\nEvidence for H7 and other coils for the treatment of Addictions\n\nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKER:\nAron Tendler\, MD\n\nDr. Aron Tendler is board certified in general psychiatry\, sleep medicine\, and obesity medicine. He sees patients thirty hours a week\, in his private practice and spends thirty hours a week on research and education as the Chief Medical Officer for BrainsWay. \nDr. Tendler's private practice is focused on helping patients who want to improve their functioning and are willing to change their treatment regimen when they are not doing well. \nDr. Tendler's research over the last twelve years has advanced the field of psychiatry forward by gaining regulatory clearance and reimbursement with effective brain-based treatments for patients with depression and obsessive compulsive disorder. He believes a greater understanding of physics and neuroscience will improve patient care and reduce stigma for patients with all neuropsychiatric disorders.
URL:https://clinicaltmssociety.org/event/deep-tms-with-the-h7-coil-over-the-dorsomedial-pfc/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/April_4_GRWS_Slide_Banner_Jan_23_GRWS_Slide_Banner_300x150.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20230307T200000
DTEND;TZID=UTC:20230307T210000
DTSTAMP:20260405T182537
CREATED:20241022T131720Z
LAST-MODIFIED:20241022T131720Z
UID:1304-1678219200-1678222800@clinicaltmssociety.org
SUMMARY:Emerging Transcranial Ultrasound Neuromodulation Technologies
DESCRIPTION:You're invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Emerging Transcranial Ultrasound Neuromodulation Technologies\, featuring Hong Chen! \nTranscranial ultrasound neuromodulation is an emerging technology with increasing clinical investigations. Ultrasound can penetrate the skull without surgery and focus its energy with high spatial precision anywhere in the brain. In addition\, ultrasound neuromodulation has the unique capability to achieve noninvasive\, spatially targeted\, and deep brain neuromodulation. This talk will introduce the state of the art of ultrasound neuromodulation and discuss emerging technology developments in this field. \nTake advantage of our live Q&A session at the conclusion of the webinar! \nAt the end of this presentation\, participants will be able to identify the following:  \n\nWhat is transcranial ultrasound neuromodulation\nWhy this technology is the state of the art\nEmerging technology developments\n\nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKER:\nHong Chen\, PhD\n\nDr. Chen is a world-leading scientist in developing innovative therapeutic ultrasound technologies and an Associate Professor of Biomedical Engineering at Washington University in St. Louis. She earned her Ph.D. degree in Bioengineering from the University of Washington in 2011. Dr. Chen was a postdoctoral research scientist in the Department of Biomedical Engineering at Columbia University from 2012 to 2015. Since joining Washington University in St. Louis in 2015\, her research has focused on developing ultrasound-brain interfacing techniques for diagnosing and treating brain diseases and understanding brain functions. Her research has been funded by NIH BRAIN Initiative\, NIBIB\, NIA\, NIMH\, NCI\, NSF\, and DoD. \nShe currently serves on the Board of Directors for the International Society of Therapeutic Ultrasound\, the IEEE International Ultrasonics technical committee\, and the Acoustical Society of America Biomedical Ultrasound technical committee. She has received numerous awards\, including the Frederic Lizzi Early Career Award from the International Society of Therapeutic Ultrasound\, the Young Investigator Award at the International Symposium on Focused Ultrasound\, and Outstanding Teaching Award.
URL:https://clinicaltmssociety.org/event/emerging-transcranial-ultrasound-neuromodulation-technologies/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/March_7_GRWS_Slide_Banner_V3.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20230207T200000
DTEND;TZID=UTC:20230207T210000
DTSTAMP:20260405T182537
CREATED:20241022T132218Z
LAST-MODIFIED:20241022T132218Z
UID:1306-1675800000-1675803600@clinicaltmssociety.org
SUMMARY:rTMS for Pain: From Clinical Guidelines to Practical Challenges
DESCRIPTION:This presentation will overview the current rTMS treatment guidelines for pain\, review various challenges related to the treatment for pain and headache management\, and discuss measures to overcome these highly relevant issues. \nYou’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: rTMS for Pain: From Clinical Guidelines to Practical Challenges\, featuring Albert Leung\, MD! \nEmerging evidence supports the use of rTMS for pain and headache management. However\, pain and headache rTMS treatment protocols differ in many ways from those used for depression or other psychiatric conditions. In the upcoming Grand Round presentation\, Dr. Leung\, a pain specialist\, Professor of Anesthesiology and Pain Medicine\, will overview the current rTMS treatment guideline for pain and review various challenges related to the treatment for pain and headache management and discuss measures to overcome these highly relevant issues. \nDon't miss out on our Q&A portion of the webinar! \nAt the end of this presentation\, participants will be able to identify:  \n\nThe current clinical rTMS treatment guidelines for headache and pain;\nReview practice-related issues using rTMS for pain and headache;\nDiscuss measures and identify resources to address these highly relevant issues.\n\nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKER: \nAlbert Y. Leung\, MD\n \nDr. Leung is a Professor of Anesthesiology and Pain Medicine at the University of California\, San Diego\, School of Medicine. In addition\, he is the Director of the Center for Pain and Headache Research at the VA San Diego Healthcare System (VASDHS) and a Research Scientist for the Veteran Medical Research Foundation. \nDr. Leung receives funding from the DOD\, VA Office of Research and Development\, and NIH for his ongoing research focusing on the mechanisms and effectiveness of non-invasive brain and peripheral stimulation for nerve function restoration and headache/pain relief. He founded the first Transcranial Magnetic Stimulation (TMS) clinical unit for pain and headache treatment in the VA healthcare system over a decade ago. He now directs the Center for TMS at the VASDHS.
URL:https://clinicaltmssociety.org/event/rtms-for-pain-from-clinical-guidelines-to-practical-challenges/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/February_7_GRWS_Slide_Banner_V2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230118
DTEND;VALUE=DATE:20230119
DTSTAMP:20260405T182537
CREATED:20241107T205200Z
LAST-MODIFIED:20241108T134240Z
UID:1537-1674000000-1674086399@clinicaltmssociety.org
SUMMARY:January 18\, 2023 Town Hall Member Meeting
DESCRIPTION:January 18\, 2023 Annual Town Hall Member Meeting  \nYou’re invited to join the Clinical TMS Society for the January 18\, 2023 Annual Town Hall Member Meeting.  \nPresentation Overview:  \nJoin the Clinical TMS Society President Mohamed Abdelghani\, MBBCh\, MSc\, FRCPsych\, FCTMSS\, Executive Director Ashleigh Servadio\, and our current committee co-chairs for an update on all 2022-2023 committee projects. \nThis is your opportunity to learn more about the various goals and projects\, ask questions and provide feedback. \nDate: January 18\, 2023 \nFormat: Zoom Meeting \nThis meeting is for current members only.  \n\nSPEAKERS:  \nBob Sammons\, MD\, PhD\, CTMSS Annual Meeting Committee Co-chair\nDr. Sammons received a bachelors and master’s degree from Auburn University\, a PhD in clinical psychology from the University of North Carolina at Greensboro\, and a medical degree from the University of North Carolina at Chapel Hill. He did a residency in psychiatry at the University of Virginia as well as a forensic psychiatry fellowship. While a Captain in the Air Force he helped set up and run the treatment phase of the Air Force Drug Treatment program in1971. He practiced adult psychiatry in Grand Junction for 30+ years. He received training in Transcranial Magnetic Stimulation in 2006 from Dr. Alvaro Pascual-Leone\, from Dr. Mark George in 2017 and returned to Harvard for Dr. Pascual-Leone’s intensive course in TMS in 2018. He is Medical Director for TMS Solutions with fourteen TMS offices in various locations in the West. He is on the national Clinical TMS Society Board of Directors\, sits on three national committees and is Chairman of the 2022 Annual Meeting. He has been known to cook a little BBQ. \nTracy Barbour\, MD\, CTMSS Clinical Standards Committee Co-chair\nDr. Barbour is the Medical Director of the Massachusetts General Hospital Transcranial Magnetic Stimulation (TMS) clinical service and an Instructor in Psychiatry at Harvard Medical School. Dr. Barbour’s research interests focus on addressing ways of improving treatment outcomes using Transcranial Magnetic Stimulation (TMS) through individualized treatment planning. Dr. Barbour received her medical degree from Wayne State University School of Medicine in Detroit\, Michigan\, and completed psychiatry residency at MGH/McLean combined residency program. During residency\, she served as the chief resident of McLean Hospital’s Clinical Evaluation Center. \nCarlos Lowell\, DO\, CTMSS Education Co-chair\nDr. Lowell is a board-certified psychiatrist in private practice in Sandusky\, OH. He formed the fifth fully functional TMS program in Ohio in 2013 and was the first osteopathic physician to start a program in Ohio; since then\, he has been the medical director of the TMS Institute of Ohio. Dr. Lowell is a member of the Clinical TMS Society (CTMSS)\, an international organization of more than 1\,000 members whose mission is to optimize the clinical practice\, accessibility\, and awareness of TMS. He is currently serving on the membership and education committees; resident task force and has served on the clinical standards committee for the Clinical TMS Society. One of Dr. Lowell's goals is to get the word out about TMS to the osteopathic profession during his tenure\, and he says he looks forward to working with osteopathic educators across the country. \nBaron Short\, MD\, CTMSS Insurance Co-chair\nDr. Short is a Psychiatry Specialist in Charleston\, SC\, and has over 21 years of medical experience\, with extensive experience in Addiction & Substance Abuse\, and Psychotic Disorders. He graduated from the MEDICAL UNIVERSITY OF SOUTH CAROLINA in 2001 and is affiliated with MUSC Health University Medical Center. His office accepts new patients. \nIan Cook\, MD\, DLFAPA\, FCTMSS\, CTMSS Legal Business Ethics Co-chair\nDr. Cook received his medical degree from Yale and completed his residency at the UCLA Neuropsychiatric Institute (now the UCLA Semel Institute) before completing an NIMH T32 research fellowship there and joining the full-time faculty. He held the Miller Family endowed chair in Depression Research and founded the Depression Research and Clinic Program in 2006 and the TMS Service in 2009. At UCLA he was Chair of the Faculty for the School of Medicine and Chief of Staff of the Resnick Neuropsychiatric Hospital. In 2018 he left the University and launched the Los Angeles TMS Institute\, focused on providing advanced neuromodulation treatments in the community. He was a member of the Executive Committee on Practice Guidelines for the APA and is a Distinguished Life Fellow. He has served on the Board of Directors of the Clinical TMS Society since 2013\, has been co-chair of the Legal\, Business\, and Ethics committee since 2017\, and was elected to be an inaugural Fellow of the Society in 2022 \nSamir Ibrahim\, MBBS\, MPsych\, FRANZCP\, OAM\, CTMSS Membership Co-chair \nNate Upshaw\, MD\, CTMSS Outreach Committee Co-chair\nDr. Upshaw began his medical training at the University of Florida and Tulane University School of Medicine. After attaining his doctorate at Tulane\, Upshaw continued onto the University of South Florida School of Medicine\, where he completed his internship and residency in Psychiatry. While at the University of South Florida\, Dr. Upshaw\, under the stewardship of a forward-thinking chairman\, received training to practice TMS shortly after being FDA cleared in 2008. The department’s progressive approach eventually led to the university obtaining two of the first TMS chairs in the entire state of Florida. \nAngela Phillips\, PhD\, CTMSS Research Committee Co-chair\nDr. Phillips is a licensed therapist and clinical researcher and has worked in public\, private\, government\, and not-for-profit organizations across clinical and research-oriented roles. Dr. Phillips's clinical and research experience has included suicide prevention\, cognitive behavioral and mindfulness-based therapies\, teletherapy delivery\, understanding global stress during the COVID-19 pandemic\, integrated therapeutics\, and treatments such as non-invasive brain stimulation for more severe psychiatric or neurological conditions. In addition\, Dr. Phillips has co-developed and led randomized and controlled trials in neuromodulation and has provided consultation and training for new providers\, centers\, and academic centers entering collaborative psychiatric and behavioral healthcare using novel treatment interventions and approaches. Additionally\, she is excited to cohost our new podcast\, Dear Mind\, You Matter\, focusing on creating greater awareness and access to various mental health and wellness tools. \nSPECIAL COMMITTEES: \nRandy Pardell\, MD\, DLFAPA\, FCTMSS\, CTMSS FACTMS Committee Chair\nDr. Pardell is currently the Immediate Past-President of the Clinical TMS Society.  He has served on the Board of Directors of CTMSS for the past 5 years. He has been past Chairman of the Outreach Committee and has served on the Membership and Education Committees. He has been a returning lecturer for the CTMSS Pulses Course. He has been practicing TMS therapy since 2009. He co-wrote the first lay book on TMS called 3000 Pulses. Dr. Pardell is an honors graduate of the University of Pennsylvania and New York University School of Medicine. He completed his residency and chief residency at the St. Luke’s Roosevelt Medical Center and Post-Doctoral Fellowship at Columbia University where he performed smoking cessation research with Alexander Glassman MD. After graduation from his psychiatric training\, Dr. Pardell moved up with his wife to the beautiful Hudson Valley\, New York to start a practice and raise a family. Dr. Pardell is a Distinguished Life Fellow of the American Psychiatric Association and has been a past President of the Mid-Hudson Psychiatric Society and had been its Program Director for over a decade. Dr. Pardell founded Riverview Psychiatric Medicine\, PC and TMS Center of the Hudson Valley and leads an active group psychiatric and TMS practice.  \nRebecca Allen\, MD\, MPH\, CTMSS Identity Committee Chair\nDr. Allen graduated with a B.A. in Psychology with honors from Stanford University. She attended Oregon Health and Science University for medical school and earned a Masters of Public Health in biostatistics and epidemiology. She completed her psychiatry residency at the Harvard Longwood Psychiatry Residency Training Program\, a joint program between Brigham and Women’s Hospital\, Beth Israel Deaconess Medical Center\, and Massachusetts Mental Health Center. She served as Chief Resident of the psychiatry consult service at Beth Israel Deaconess Medical Center. She then completed a 2-year fellowship in Neuropsychiatry at Brigham and Women’s Hospital. She has participated in research on sleep and memory consolidation\, quality of life in multiple sclerosis\, the efficacy of different TMS protocols\, EEG biomarkers of TMS response\, the RECOVER VNS trial\, and other projects. She has authored several papers. Dr. Allen has had several roles with the Clinical TMS Society\, including serving on the Board of Directors\, as the Treasurer\, as Co-Chair of the Insurance Committee\, and as Vice President. She was presented with a service award from the CTMSS in 2021. \nDebra Stultz\, MD\, CTMSS Budget & Finance\, and Structure Committee Chair\nDr. Stultz is the Director and Owner of Stultz Sleep and Behavioral Health in Barboursville\, West Virginia. Dr. Stultz earned her medical degree from Marshall University School of Medicine in Huntington\, West Virginia. She completed a residency in psychiatry and a fellowship in child/adolescent psychiatry through West Virginia University at their Charleston Division through Charleston Area Medical Center in Charleston\, West Virginia. She is board certified in psychiatry\, sleep medicine\, and behavioral sleep medicine.  With a special interest in Narcolepsy\, she treats a variety of sleep disorders and psychiatric issues.  Her specialty in psychiatry is treatment-resistant depression. She is also the editor for the Clinical TMS Society Newsletter\, on their Board of Directors\, Co-Chair of the Education Committee\, and the chairman of the TMS and Sleep Disorders Affinity Group. \nMODERATED BY:  \nMohamed Abdelghani\, MBBCh\, MSc\, FRCPsych\, FCTMSS\, CTMSS President \nDr. Abdelghani completed his post-graduate psychiatric training at South London & Maudsley NHS Foundation trust (SLaM) which is the biggest mental health trust in the UK\, a center of excellence and one of the most influential mental health organizations in the world. During his training at SLaM he worked alongside some of the most prominent professors and clinicians in the field. Dr. Abdelghani worked at the National Affective Disorders Service\, which was one of six national affective disorders units in the UK. The time he spent on the National Affective Disorders Unit and outpatient clinic equipped him with clinical skills and excellent experience to manage and treat the most treatment resistant depressed and bipolar patients. After working in the National Affective Disorders service for a year he became involved in a multicenter international cutting edge research that tested the use of Deep Brain Stimulation (DBS) to treat treatment resistant depression. He was the primary psychiatrist at King’s College London site for this study. Neurostimulation is one of his special interests and working on this study gave him the opportunity to meet and build links with leading figures in the field around the world. Another special interest of Dr. Abdelghani is Adult ADHD.  Dr Abdelghani trained at the first Adult ADHD clinic in the UK that was opened at the Maudsley Hospital in London. \nAfter finishing his higher psychiatry training at SLaM he worked as a consultant psychiatrist for almost a year at the same organization before moving to work in central London at Camden and Islington NHS Foundation Trust. At the present time he is the Lead Consultant Psychiatrist for Adult ADHD at Camden and Islington NHS Foundation Trust besides working as a consultant psychiatrist in CDAT (Complex depression\, Anxiety and Trauma) service. Dr Abdelghani continues being actively involved in research in the field of Adult ADHD and mood disorders. He has a keen interest in spreading mental health awareness and knowledge through teaching medical students\, training junior doctors\, giving lectures to fellow psychiatrists and media interviews. \n\n\n\n\n \n \n \n\n\n\n\n\n\n\nWhen\nJanuary 18th\, 2023 from  5:00 PM to  6:30 PM
URL:https://clinicaltmssociety.org/event/january-18-2023-town-hall-member-meeting/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/11/2023_Annual_Town_Hall_Meeting_Social_Media_V2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20230103T200000
DTEND;TZID=UTC:20230103T210000
DTSTAMP:20260405T182537
CREATED:20241022T132643Z
LAST-MODIFIED:20241022T132643Z
UID:1308-1672776000-1672779600@clinicaltmssociety.org
SUMMARY:Interventional Psychiatry in Training and Clinical Practice
DESCRIPTION:This presentation will review current viewpoints on the definition and scope of practice of an interventional psychiatrist\, as well as discuss training needs\, dilemmas\, and future directions of this new subspecialty. \nYou’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: Interventional Psychiatry in Training and Clinical Practice: Definitions\, Dilemmas\, and Future Directions of a Subspecialty\, featuring Tracy Barbour\, MD! Don't miss out on our Q&A portion of the webinar! \nAt the end of this presentation\, participants will be able to identify:  \n\nThree treatment modalities that might be in the scope of practice of an interventional psychiatrist;\nThree ways of improving access to interventional psychiatry educational opportunities;\nTwo benefits of acquiring training in more than one neuromodulation modality.\n\nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKER: \nTracy Barbour\, MD\nMedical Director\nTranscranial Magnetic Stimulation (TMS) clinical service\nMassachusetts General Hospital \n\nDr. Barbour works at the Massachusetts General Hospital as the Medical Director of Transcranial Magnetic Stimulation (TMS) clinical service\, the Associate Director of the ECT service\, and the Program Director of the Interventional Neuropsychiatry and Neuromodulation Fellowship. Dr. Barbour received her medical degree from Wayne State University School of Medicine in Detroit\, Michigan\, and completed psychiatry residency at MGH/McLean combined residency program. During residency\, she served as the chief resident of McLean Hospital’s Clinical Evaluation Center. Following residency\, Dr. Barbour was awarded the Dupont-Warren Fellowship from Harvard Medical School\, to learn advanced methods in neuroimaging and neuroscience research. Clinically\, Dr. Barbour treats patients in the TMS\, ECT\, and ketamine clinical services. Her research interests focus on addressing ways of improving treatment outcomes using Transcranial Magnetic Stimulation (TMS) through individualized treatment planning. Dr. Barbour is a member of the Clinical TMS Society and services as co-chair of the Clinical TMS Society’s clinical standards committee.
URL:https://clinicaltmssociety.org/event/interventional-psychiatry-in-training-and-clinical-practice/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/January_23_GRWS_Slide_Banner_FULL.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20221206T200000
DTEND;TZID=UTC:20221206T210000
DTSTAMP:20260405T182537
CREATED:20241022T133248Z
LAST-MODIFIED:20241022T133248Z
UID:1310-1670356800-1670360400@clinicaltmssociety.org
SUMMARY:If it’s not a chemical imbalance\, then what do I have?
DESCRIPTION:This presentation will summarize recent findings on the neurobiology of depression\, and distill these findings into a narrative form that is more clearly comprehensible to practitioners and patients alike. Updated explanatory models of depression may help patients better understand their own illness\, make sense of the symptoms they experience\, and make better informed choices about which treatment options to pursue\, as neuromodulation treatments enter increasingly widespread use in the community. \nYou’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: \n"If it’s not a chemical imbalance\, then what do I have?”\, featuring Jonathan Downar\, MD\, PhD\, FRCPC! \nDon't miss out on our Q&A portion of the webinar! \nAt the end of this presentation\, participants will be able to:  \n(1) To review recent advances in our understanding of the neurobiology of depression. \n(2) To understand how these advances shed light on the mechanisms of old and new treatments for depression. \n(3) To acquire more accurate and more comprehensible updated narratives for explaining depression and its treatment to patients and members of the lay public \nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKER: \nJonathan Downar\, MD\, PhD\, FRCPC \n \nDr Jonathan Downar is an Associate Professor in Psychiatry and a Senior Fellow at Massey College at the University of Toronto.  His work over the last 25 years has spanned the translational spectrum from basic science work using functional neuroimaging to randomized controlled trials of novel treatment protocols for transcranial magnetic stimulation.  He is the senior author of the widely cited THREE-D study\, published in Lancet in 2018\, that led to formal FDA approval for 3 minute theta-burst TMS in depression.  He enjoys close collaborations with colleagues in the United States\, Canada\, Europe\, and Australia on projects dedicated to making TMS treatments more effective\, and above all more accessible\, for patients with depression and other psychiatric disorders.  The long-term objective of this work is to achieve large and measurable reductions in the worldwide prevalence of depression and mental illnesses\, within our lifetimes\, via a new generation of safe\, scalable\, and effective brain-based interventions.
URL:https://clinicaltmssociety.org/event/if-its-not-a-chemical-imbalance-then-what-do-i-have/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/December_22_GRWS_Slide_Banner_April_22_GRWS_Slide_Banner_300x150.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20221101T150000
DTEND;TZID=UTC:20221101T160000
DTSTAMP:20260405T182537
CREATED:20241022T133502Z
LAST-MODIFIED:20241022T133502Z
UID:1312-1667314800-1667318400@clinicaltmssociety.org
SUMMARY:Getting to the Heart of Precision-TMS: Brainmarkers and Heart-Brain Coupling to optimize TMS clinical outcomes.
DESCRIPTION:Given relatively modest remission rates for all antidepressant treatments available\, there is a need for approaches that help tailor existing treatments to the individual in order to improve remission rates. In addition\, such techniques should be clinically actionable and well validated in blinded out-of-sample validations. Here we introduce the concept of Stratified Psychiatry\, that is better suited for implementation in clinical practice\, and demonstrate that Brainmarker-I\, an EEG biomarker\, can successfully help stratify patients between 1-Hz right and 10-Hz left rTMS\, as well as for ECT and various other antidepressant treatments\, as a clinically actionable stratification marker.\nFurthermore\, a novel update of NCG-TMS called Heart-Brain Coupling is introduced that provides real time evidence of frontal-vagal activation\, simply measured using an iPhone app. This technique not only helps identify the right target for frontal-vagal activation\, but also provides frontal excitability thresholds (which are known to differ substantially from motor-thresholds). \nYou’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: Getting to the heart of precision-TMS: Brainmarkers and Heart-Brain Coupling to optimise TMS clinical outcomes\, featuring Martijn Arns\, PhD! \nDon't miss out on our Q&A portion of the webinar! \nAt the end of this presentation\, participants will be able to:  \n(1) How specific TMS stimulation can directly influence heart rate via heart-brain coupling; \n2) How the motor threshold is different from frontal excitability thresholds; and \n3) How specific EEG frequencies can be instrumental in stratifying patients between 1-Hz and 10-Hz rTMS. \nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKER: \nMartijn Arns\, PhD \n \nDr. Arns graduated in the late 90’s as a biological psychologist and in 2011 received his PhD at Utrecht University on the topic of 'EEG-based personalized medicine for ADHD and depression'. He is founder and research director at the non-profit Brainclinics Foundation\, associate professor at Maastricht University\, Section Brain Stimulation and Cognition and scientific adviser to neurocare group.
URL:https://clinicaltmssociety.org/event/getting-to-the-heart-of-precision-tms-brainmarkers-and-heart-brain-coupling-to-optimize-tms-clinical-outcomes/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/November_22_GRWS_Slide_Banner_April_22_GRWS_Slide_Banner_300x150.png
END:VEVENT
END:VCALENDAR